Evidence map›Paper›PMID 41095854›Full record

ArticleJournal of clinical medicine2025

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study.

Sławomir Teper, Daniel Ledwoń, Patrycja Romaniszyn-Kania, Adam Sendecki, Aleksandra Tuszy, Julia Nycz, Andrzej W Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sławomir TeperChair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-0935-8880
Daniel LedwońFaculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, Poland.ORCID 0000-0001-7704-2901
Patrycja Romaniszyn-KaniaFaculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, Poland.ORCID 0000-0003-1689-4347
Adam SendeckiChair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0001-7605-8653
Aleksandra TuszyFaculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, Poland.ORCID 0009-0005-1334-0236
Julia NyczInstitute of Biomedical Engineering and Informatics, Technische Universität Ilmenau, 98693 Ilmenau, Germany.ORCID 0000-0001-6031-1423
Andrzej W MitasFaculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, Poland.ORCID 0000-0001-7833-5845
Małgorzata FigurskaDepartment of Ophthalmology, Military Institute of Medicine, Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, Poland.ORCID 0000-0002-6366-802X
Edward WylęgałaChair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-6707-5790
Marek RękasDepartment of Ophthalmology, Military Institute of Medicine, Central Clinical Hospital of the Ministry of National Defense, 04-141 Warsaw, Poland.ORCID 0000-0003-0429-6649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-VEGF therapynational treatment registryneovascular AMDreal-world evidencetreatment outcomes

Identifiers

PMID41095854
PMCPMC12524941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.